Inhibition of Retinopathy and Retinal Metabolic Abnormalities in Diabetic Rats With AREDS-Based Micronutrients

Renu A. Kowluru, MS, PhD; Mamta Kanwar, MS; Pooi-See Chan, PhD; Jiang Ping Zhang, MD

Objectives: To investigate whether the micronutrients that were shown to reduce the risk of development of age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) can have the same effect on the development of diabetic retinopathy in rats, and to understand the possible mechanisms.

Methods: Streptozotocin-induced diabetic rats received a powdered diet with or without supplemental micronutrients (ascorbic acid, vitamin E, beta-carotene, zinc, and copper). The retina was used after the rats had diabetes for 12 months to detect vascular histopathology and to measure the biochemical parameters and messenger RNA levels of the genes involved in oxidative and nitrative stress.

Results: The AREDS-based micronutrients prevented a diabetes-induced increase in the number of retinal acellular capillaries. In the same rats, micronutrients inhibited increases in retinal oxidatively modified DNA and nitrotyrosine and decreases in manganese superoxide dismutase. Diabetes-induced alterations in the messenger RNA expression of mitochondrial electron transport complex III (coenzyme Q cytochrome-c reductase) and inducible nitric oxide synthase were also prevented.

Conclusion: Age-Related Eye Disease Study–based micronutrients inhibit the development of diabetic retinopathy in rodents by inhibiting oxidative and nitrative stress.

Clinical Relevance: Micronutrients that slow down the onset and progression of age-related macular degeneration have the potential to inhibit the development of diabetic retinopathy.

Arch Ophthalmol. 2008;126(9):1266-1272

Diabetic retinopathy is the major cause of blindness in working adults in developed countries, and high glucose is considered the main instigator in its development. Good glycemic control can prevent and/or retard diabetic retinopathy,1-3 but such control is difficult to achieve and maintain. Many biochemical and molecular sequelae of hyperglycemia have been implicated in the pathogenesis of diabetic retinopathy;4-8 however, the exact mechanism remains elusive.

Oxidative stress is elevated in the retina in diabetes, and increased oxidative stress contributes to the development of diabetic retinopathy.7,8 Increase in reactive oxygen species is considered a causal link between elevated glucose and other metabolic abnormalities important in the development of diabetic retinopathy.9 Various antioxidants and nutrients have provided encouraging results in experimental models of diabetic retinopathy,7,8,10-13 though the results from clinical trials have been less conclusive.14-16 In diabetic mice, overexpression of the enzyme responsible for scavenging mitochondrial superoxide, manganese superoxide dismutase (MnSOD), prevents early lesions of retinopathy.10 In diabetic rats, supplementation with multiantioxidants or lipoic acid inhibits the development of retinopathy, and green tea and benfotiamine (a vitamin B1 derivative) inhibit the formation of increased acellular capillaries.7,8,10,12

The Age-Related Eye Disease Study (AREDS) has demonstrated that micronutrients, including antioxidants and trace metals, can reduce the risk of developing a blinding disease, age-related macular degeneration (AMD).17-19 The purpose of our study is to investigate the effect of the same AREDS-based micronutrients on the development of retinopathy in rats with streptozotocin-induced diabetes and to understand the possible mechanism through which these nutrients elicit their beneficial effects.
Nitrotyrosine, a measure of peroxynitrite formed by reaction between superoxide and nitric oxide (NO), was quantified in the retina by enzyme immunoassay.\textsuperscript{21,22} Nitrotyrosine standard or retinal homogenates were incubated with a nitrotyrosine antibody in the microplate for 1 hour, followed by incubation with streptavidin peroxidase for 1 hour. The samples were incubated with tetramethylbenzidine substrate for 30 minutes. The reaction was stopped by 2.0M citric acid, and absorbance at 450 nm was monitored.

The enzyme activity of superoxide dismutase was measured by a method used in our laboratory.\textsuperscript{21} Activity of MnSOD was calculated by performing the assay in the presence of potassium cyanide to inhibit copper-zinc superoxide dismutase, thus measuring the residual MnSOD activity.

TOTAL RNA ISOLATION AND MESSENGER RNA QUANTIFICATION

Total retinal RNA was isolated by TRIZol reagent (Invitrogen, Carlsbad, California). The concentration and integrity of RNA was determined spectrophotometrically. The RNA (1 µg) was converted to complementary DNA (cDNA) using the High Capacity cDNA Reverse Transcription Kit with RNase inhibitor (Applied Biosystems, Foster City, California). The cDNA was synthesized using the GeneAmp PCR 9700 thermal cycler (Applied Biosystems), quantified spectrophotometrically, and diluted to 10 ng/µL.\textsuperscript{22}

Quantitative real-time polymerase chain reaction (PCR) for genes for MnSOD, catalase, complex III (coenzyme Q cytochrome-c reductase), and an inducible form of NO synthase (iNOS) was performed using the TaqMan Assays on Demand for rats (Applied Biosystems). The β2-macroglobulin was used as a housekeeping gene. Real-time PCR was performed in 96-well plates using the ABI-7500 sequence detection system (Applied Biosystems), and each sample was analyzed in triplicate. The cDNA templates were combined with the TaqMan assay and TaqMan Universal PCR Master Mix (Applied Biosystems) and amplified. The standard PCR conditions were 2 minutes at 50°C and 10 minutes at 93°C followed by 40 cycles of extension at 93°C for 15 seconds and 1 minute at 60°C. Threshold lines were automatically adjusted to intersect amplification lines in the linear portion of the amplification curves. Data were normalized with β2-macroglobulin, and the fold change in gene expression relative to normal was calculated using the ddCt (ΔΔCt cycles threshold) method.\textsuperscript{21}

STATISTICAL ANALYSIS

Each measurement was made at least in duplicate, and the values are expressed as mean (standard deviation). Parameters were analyzed using the nonparametric Kruskal-Wallis test followed by Mann-Whitney U test. Histopathology data were also analyzed by analysis of variance and similar conclusions were yielded. A P value of less than .05 was considered statistically significant.

PREVENTION OF DIABETES-INDUCED HISTOPATHOLOGY IN THE RETINA

Duration of diabetes of 12 months in rats increased the number of degenerative (acellular) capillaries in the retinal vasculature 2.5-fold compared with control rats (Figure 1). This increase was prevented in rats with diabetes who received micronutrients (P= .03); the num-
The number of acellular capillaries was similar in the retinas of control rats and those in the diabetes and AREDS group (\(P = .92\)).

**INHIBITION OF OXIDATIVE STRESS IN THE RETINA**

Because oxidative stress is implicated in the development of diabetic retinopathy, the effect of the micronutrients on the parameters of oxidative stress in the retina was investigated.

The levels of 8-OHdG were elevated by 45% in the retinas obtained from rats with diabetes compared with those of the control rats. Elevation in retinal 8-OHdG levels was prevented when rats with diabetes were administered AREDS-based micronutrients; 8-OHdG levels in the control rats were comparable with those in the diabetes and AREDS group (\(P > .05\); Figure 2A).

Nitrotyrosine levels were elevated by 80% in the retinas of rats who had diabetes for 12 months, and supplementation with AREDS-based micronutrients had a significant beneficial effect on such increases. Retinal nitrotyrosine levels in rats in the diabetes and AREDS group were significantly lower than those in the rats with diabetes who were not given micronutrients (Figure 2B).

As expected, 12 months of having diabetes decreased the activity of MnSOD by about 35% in the retinas of rats with diabetes compared with control rats (Figure 3). Micronutrients prevented this diabetes-induced decrease in retinal MnSOD; the values of the control group and the group with diabetes and AREDS were not different from each other (\(P > .05\)).

**MODULATION OF ALTERATIONS IN THE EXPRESSION OF OXIDATIVE STRESS–RELATED GENES**

To determine if the micronutrients had beneficial effects on the prevention of diabetes-induced alterations in mRNA levels of MnSOD, gene expression of MnSOD was quantified. Twelve months of having diabetes decreased mRNA levels of MnSOD in rats by about 30%, and the micronutrients prevented a diabetes-induced decrease in MnSOD messenger RNA (mRNA) levels (Figure 4A). The expression of MnSOD (determined by Western blot) also decreased by about 33% in the reti-
nas of rats with diabetes compared with control rats; this reduction was restored to levels similar to normal values in the rats with diabetes who received the micronutrients (data not shown). Similarly, mRNA expression of another antioxidant defense enzyme, catalase, decreased by 30% in the retinas of rats with diabetes; however, AREDS-based micronutrients had no beneficial effect on this decrease (Figure 4B).

One of the sources of increased superoxide in the retinas of rats with diabetes is the impaired complex III activity, and increased retinal NO in diabetes is due to increased iNOS. Figure 5A shows that mRNA expression of complex III was decreased by 35% in rats with diabetes. The mRNA expression of iNOS was elevated approximately 7-fold (Figure 5B). Supplementation with micronutrients prevented a diabetes-induced decrease in complex III mRNA by more than 90% and partially, but significantly, prevented an increase in iNOS gene expression (approximately 50%; P < .002).

EFFECT OF AREDS-BASED MICRONUTRIENTS ON THE SEVERITY OF HYPERGLYCEMIA IN ANIMALS WITH DIABETES

To ensure that the severity of hyperglycemia was similar between the rats with diabetes that were and those that were not treated with AREDS-based micronutrients, insulin dosage was adjusted 3 to 4 times per week, depending on body weight and food consumption. Body weights for the entire duration of the experiment in the diabetes and AREDS group were not different from those of the diabetes group (Table). Glycated hemoglobin, an index of long-term glycemic control, was also similar in the 2 diabetic groups. Rats with diabetes had 10-fold higher urine output compared with control rats; this was not ameliorated by micronutrient supplementation. Similarly, blood glucose values in the diabetes and AREDS group were not different from those of the diabetes group; these values were significantly higher than those of the control rats (data not shown).

COMMENT

This is the first study demonstrating that the nutritional supplements that slow down onset and/or progression of AMD, the leading cause of blindness in the elderly population, also inhibit the development of another sight-threatening disease, diabetic retinopathy (a major cause of blindness in young adults). The possible mechanism by which these nutrients inhibit diabetic retinopathy appears to involve inhibition of oxidative stress.

Formation of degenerative capillaries represents one of the early features of retinopathy seen in rodents with diabetes. Our exciting data show that the increased appearance of acellular capillaries in the retinal vasculature can be inhibited significantly by AREDS-based nutritional supplements. These results could have immense clinical implications because they suggest that the development and/or progression of a multifactorial com-
plication that affects more than 80% of diabetic patients can be retarded by nutritional supplements that are already being tested for treatment of AMD. Oxidatively modified DNA is one of the most frequently used and reliable indicators of oxidative damage. Increased levels of 8-OHdG in the retina are implicated in the pathogenesis of diabetic retinopathy. Inhibition of the early lesions of diabetic retinopathy by lipoic acid administration in rats or by overexpression of MnSOD in mice is postulated to be caused by inhibition of retinal 8-OHdG levels. We show that AREDS-based micronutrients can also have beneficial effects on elevated retinal 8-OHdG levels, suggesting that these micronutrients could be inhibiting the development of diabetic retinopathy, in part by inhibiting the accumulation of oxidized DNA in the retina.

Peroxynitrite, produced from the diffusion-controlled reaction between NO and a superoxide anion, interacts with lipids, DNA, and proteins via direct oxidative reactions or indirect, radical-mediated mechanisms. These reactions, in turn, can modulate cell signaling and increase oxidative stress. Thus, the pathological implications of peroxynitrite have subtle and specific actions on cells. Nitrative stress is increased early in the course of development of retinopathy in diabetes, and the therapies that inhibit the activation of the apoptosis execution enzyme and the development of retinopathy in rats with diabetes decrease retinal nitrative stress. The AREDS-based micronutrients inhibit the development of diabetic retinopathy and nitrotyrosine level; this supports the role of peroxynitrite in the development of diabetic retinopathy.

Manganese superoxide dismutase is considered the first line of defense against increased mitochondrial superoxide. Its enzyme activity and mRNA are decreased in the retina in rats with hyperglycemia. Overexpression of MnSOD inhibits retinal oxidative stress and retinopathy in mice with diabetes, and supplementation with antioxidants prevents decreases in MnSOD in the retinas of rats. Beneficial effects of the micronutrients on MnSOD suggest that these micronutrients, by regulating MnSOD, help scavenge increased retinal superoxide. Furthermore, the micronutrients also prevented a decrease in the mRNA of complex III, an enzyme responsible for release of superoxide to both sides of the mitochondrial membrane. Our recent study has suggested that complex III is one of the sources of diabetes-induced increased retinal superoxide; its activity is decreased in mice with diabetes that can be prevented by overexpression of MnSOD. Thus inhibition of the decrease in the mRNA expression of complex III strongly suggests that these micronutrients could have a beneficial effect on diabetic retinopathy by preventing mitochondrial dysfunction and decreasing accumulation of superoxide. In contrast, the same micronutrients failed to inhibit reduction of catalase mRNA expression. The reason for this failure is not clear, but is consistent with our previous results showing that supplementation with ascorbic acid and vitamin E protects the retinal vasculature from histopathology in rats with diabetes, but does not prevent a decrease in catalase activity.

Table. Effect of AREDS-Based Micronutrients on the Severity of Hyperglycemia in Rats

<table>
<thead>
<tr>
<th>Group</th>
<th>Body Weight, g</th>
<th>Food Intake, g/d</th>
<th>GHb, %a</th>
<th>Urine Volume, mL/24 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n=8)</td>
<td>412 (26)</td>
<td>23 (3)</td>
<td>4.2 (0.77)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Diabetes (n=7)</td>
<td>260 (32)</td>
<td>35 (4)</td>
<td>11.5 (1.3)</td>
<td>68 (18)</td>
</tr>
<tr>
<td>Diabetes and AREDS (n=9)</td>
<td>259 (39)</td>
<td>33 (5)</td>
<td>10.7 (2.9)</td>
<td>75 (25)</td>
</tr>
</tbody>
</table>

Abbreviations: AREDS, Age-Related Eye Disease Study; GHb, glycated hemoglobin.

aGlycated hemoglobin was quantified after 8 weeks of having diabetes and repeated every 3 months thereafter for 12 months.
bTo convert to proportion of total hemoglobin, multiply by 0.01.
Diabetes upregulates iNOS in the retina. In rodents, increased NO levels are observed early in the pathogenesis of diabetic retinopathy and remain elevated when histopathology is developing. Mice with diabetes who are iNOS-deficient are protected from retinal vascular pathology. Here we show that the mRNA of iNOS is elevated in the retina of rats with diabetes; this can be prevented by these micronutrients. This suggests that the micronutrients could be inhibiting increased retinal peroxynitrite by decreasing both superoxide and NO levels.

The whole retina was used to analyze biochemical parameters and mRNA levels; this approach did not allow us to identify the specific cell type because the retina has multiple layers and cell types. Prevention of vascular histopathology by micronutrients, however, suggests that these micronutrients had access to the retinal vasculature and thus could have exerted their beneficial effects on the development of retinopathy by inhibiting the biochemical abnormalities also in the vasculature.

The AREDS-based micronutrients consisted of multiple antioxidants and trace metals; thus the mechanism by which these micronutrients could inhibit diabetic retinopathy cannot be clearly elucidated. Vitamin E, ascorbic acid, and beta carotene inhibit diabetic retinopathy in rats, possibly by inhibiting increased oxidative stress. In addition to the antioxidants, the micronutrients had zinc oxide and copper oxide. Zinc has been shown to protect the retina from diabetes-induced increased lipid peroxidation and decreased glutathione levels in rats either by stabilizing the membrane structure or by inducing metallothionein synthesis. Zinc is essential for copper-zinc superoxide dismutase and inhibits diabetes-induced increases in plasma malondialdehyde and decreases in erythrocyte antioxidant defense enzymes. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase, and copper deficiency results in oxidative damage to lipids, DNA, and proteins. The exact mechanism by which zinc and copper exerted their protective effect against retinal damage is not clear, but the possibility that these nutrients are helping to decrease oxidative damage remains very strong.

Our results demonstrate that AREDS-based micronutrients inhibit the lesions associated with diabetic retinopathy in rats, despite similar severity of hyperglycemia in the diabetes and diabetes and AREDS groups. These beneficial effects cannot be attributed to amelioration of the severity of hyperglycemia. Glycated hemoglobin values were similar in the 2 diabetic groups and were significantly higher than those obtained from age-matched control rats, suggesting that glycation of proteins is not influenced by these micronutrients.

Inhibition of the development of diabetic retinopathy, a long-term disease, requires a therapy that is safe and easily tolerable. We did not observe any significant effect of these micronutrients on the morbidity and mortality of rats with diabetes, suggesting that the nutrients were not toxic, but in clinical settings, patients should be made aware of any possible shortcomings from a long-term use of this therapy for this progressive disease. Animal models have provided promising results with antioxidants, though results from clinical studies have been ambiguous. Intake of antioxidants, based on diet recall by diabetic patients, is ineffective in treating diabetic retinopathy. The differences for such discrepancies are not clear, but the possibility that the initiation of antioxidants could be subsequent to the development of background retinopathy, in contrast to the animal studies in which antioxidants are administered soon after establishment of diabetes, or that the antioxidant concentrations achieved in the retina of patients were not sufficient to produce beneficial effects, cannot be ruled out. The results presented here are from a preventive study, but the effect of these micronutrients in diabetic animals with early alteration in the blood-retinal barrier could be very informative. Nutritional supplements have become the first line of defense for clinicians in treating dry AMD. We show that the same micronutrients have the potential to prevent the development of diabetic retinopathy. Our novel findings are the first step toward testing the same micronutrients in clinical settings; this could be welcome news for patients with diabetes. The use of nutritional supplements, if successful, will be a major step forward in fighting this sight-threatening complication that patients with diabetes fear.

Submitted for Publication: January 29, 2008; final revision received March 25, 2008; accepted March 29, 2008.

Correspondence: Renu A. Kowluru, MS, PhD, Kresge Eye Institute, Wayne State University, 4717 St Antoine, Detroit, MI 48201 (rkowluru@med.wayne.edu).

Financial Disclosure: None reported.

Funding/Support: This study was supported in part by grants 014370 and E017313 from the National Institutes of Health, grant 2004-287 from the Juvenile Diabetes Research Foundation, the Thomas Foundation, and Research to Prevent Blindness.

REFERENCES

3. Hammes H-P, Kinzing I, Wiegand S, Bretzel RG, Cohen AM, Federlin K. Islet transplantation inhibits diabetes-induced increases in plasma malondialdehyde and decreases in erythrocyte antioxidant defense enzymes. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase. Copper oxide functions as the active center of many cuproenzymes, including copper-zinc superoxide dismutase.
12. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major path-


---

A. A 35-year-old woman had decreased vision related to a temporal optic disc pit. B. Optical coherence tomography (Stratus OCT 3; Zeiss, Jena, Germany) showed a schisis of the retina connected to the pit, cystic cavities in the inner layers of the retina, and an outer macular hole, without visible traction of the vitreous.